NOVEL MEDITOPES AND RELATED MEDITOPE-MONOCLONAL ANTIBODY DELIVERY SYSTEMS, SYNTHESIS AND THERAPEUTIC USES THEREOF
First Claim
1. ) A meditope variant comprising a peptide having one or more modifications of at least one amino acid residue of the sequence CQFDLSTRRLKC (SEQ ID NO:
- 1) or CQYNLSSRALKC (SEQ ID NO;
2).
3 Assignments
0 Petitions
Accused Products
Abstract
Meditope variants and methods for their use are provided herein. A meditope variant as described herein comprises a peptide having a sequence CQFDLSTRRLKC (SEQ ID NO:1) or CQYNLSSRALKC (SEQ ID NO:2) that has one or more modifications at of least one amino acid residue of the sequence. Multivalent meditope variant tethering entities are also provided. Such entities may include two or more meditopes coupled via a long linker, multivalent scaffold, biotin-streptavidin, or IgG Fc domain. Further, methods of treating, imaging or diagnosing a disease or condition are provided. Such methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, the pharmaceutical compound comprising an antibody-meditope complex; a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof; or a combination thereof.
6 Citations
28 Claims
-
1. ) A meditope variant comprising a peptide having one or more modifications of at least one amino acid residue of the sequence CQFDLSTRRLKC (SEQ ID NO:
- 1) or CQYNLSSRALKC (SEQ ID NO;
2). - View Dependent Claims (2, 3, 4)
- 1) or CQYNLSSRALKC (SEQ ID NO;
- 5. ) A multivalent meditope variant tethering entity comprising two or more meditopes coupled via a long linker, multivalent scaffold, biotin-streptavidin, a nanoparticle, a polynucleotide sequence, peptide nucleic acid, an organic polymer, or IgG Fc domain.
-
12. ) A composition comprising a meditope or meditope variant of one or more of SEQ ID NOS:
- 1, 2, and 5-40 conjugated to one or more therapeutic substances, imaging substances or a combination thereof.
- View Dependent Claims (13, 14, 15)
-
16. ) A method of purifying a monoclonal antibody or functional fragment thereof, comprising:
-
coupling a meditope variant to a solid support; contacting the coupled meditope variant with a solution containing or suspected of containing the monoclonal antibody or functional fragment thereof such that the monoclonal antibody or functional fragment thereof binds the meditope. - View Dependent Claims (17, 18)
-
-
19. ) A method of treating, imaging or diagnosing a disease or condition comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject, the pharmaceutical composition comprising an antibody-meditope complex;
- a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof;
or a combination thereof, wherein the antibody-meditope complex and the multivalent tethering agent comprise a meditope variant. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26)
- a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof;
-
27. ) A method of targeting cells overexpressing a cancer biomarker, comprising administering a therapeutic amount of a meditope-enabled monoclonal antibody or a functional fragment thereof in combination with a meditope variant or a multivalent tethering agent to a population of cells overexpressing or suspected of overexpressing the biomarker.
-
28. ) The method of 27, wherein the cancer biomarker is EGFR and the meditope-enabled monoclonal antibody is cetuximab.
Specification